US 11,926,660 B2
Anti-ApoE antibodies
David Holtzman, St. Louis, MO (US); Hong Jiang, St. Louis, MO (US); Thu Nga Bien-Ly, South San Francisco, CA (US); Mark S. Dennis, South San Francisco, CA (US); Jing Guo, South San Francisco, CA (US); Adam P. Silverman, South San Francisco, CA (US); Ryan J. Watts, South San Francisco, CA (US); and Yin Zhang, South San Francisco, CA (US)
Assigned to Washington University, St. Louis, MO (US)
Filed by Washington University, St. Louis, MO (US)
Filed on Aug. 24, 2021, as Appl. No. 17/410,686.
Application 17/410,686 is a continuation of application No. 16/345,637, granted, now 11,124,562, previously published as PCT/US2017/058874, filed on Oct. 27, 2017.
Claims priority of provisional application 62/414,413, filed on Oct. 28, 2016.
Claims priority of provisional application 62/533,336, filed on Jul. 17, 2017.
Prior Publication US 2022/0411485 A1, Dec. 29, 2022
This patent is subject to a terminal disclaimer.
Int. Cl. C07K 16/28 (2006.01); A61K 9/00 (2006.01); A61K 9/127 (2006.01); A61K 31/192 (2006.01); A61K 39/00 (2006.01); A61P 25/28 (2006.01); C07K 16/18 (2006.01)
CPC C07K 16/18 (2013.01) [A61K 9/0019 (2013.01); A61K 9/0085 (2013.01); A61K 9/127 (2013.01); A61K 31/192 (2013.01); A61P 25/28 (2018.01); A61K 2039/505 (2013.01); C07K 2317/33 (2013.01); C07K 2317/90 (2013.01); C07K 2317/92 (2013.01)] 8 Claims
OG exemplary drawing
 
1. An isolated anti-ApoE antibody comprising (a) a light chain variable region comprising CDRL1 of SEQ ID NO: 51, CDRL2 of SEQ ID NO: 24, and CDRL3 of SEQ ID NO: 25; and (b) a heavy chain variable region comprising CDRH1 of SEQ ID NO: 52, CDRH2 of SEQ ID NO: 53, and CDRH3 of SEQ ID NO: 54.